LifeTech Scientific (FRA:81X) ROCE %: 8.88% (As of Dec. 2025)


FRA:81X LifeTech Scientific Corp FRA:81X
96 GF Score
Price €0.14
GF Value €0.21
! 4 Warning Signs
View Full Analysis

What is LifeTech Scientific ROCE %?

LifeTech Scientific FRA:81X -0.71% 96 ROCE % is 8.88% as of Dec. 2025. GuruFocus rates FRA:81X with a GF Score™ of 96/100 and a GF Value™ of €0.21. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LifeTech Scientific's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.88%.

LifeTech Scientific  (FRA:81X) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

LifeTech Scientific ROCE % Related Terms

LifeTech Scientific ROCE % Historical Data

* Premium members only.

The historical data trend for LifeTech Scientific's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeTech Scientific ROCE % Chart

LifeTech Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.62 12.88 4.90 5.07 4.82

LifeTech Scientific Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.37 7.89 2.23 0.79 8.88
FRA:81X
96GF Score
LifeTech Scientific Corp FRA:81X
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LifeTech Scientific ROCE % Calculation

LifeTech Scientific's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=23.24/( ( (642.776 - 106.986) + (607.765 - 179.381) )/ 2 )
=23.24/( (535.79+428.384)/ 2 )
=23.24/482.087
=4.82 %

LifeTech Scientific's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=42.286/( ( (644.018 - 119.932) + (607.765 - 179.381) )/ 2 )
=42.286/( ( 524.086 + 428.384 )/ 2 )
=42.286/476.235
=8.88 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.88% mean?
LifeTech Scientific (FRA:81X) has a ROCE % of 8.88% as of Dec. 2025.
Is LifeTech Scientific's ROCE % too high?
LifeTech Scientific's current ROCE % is 8.88%. The Medical Devices & Instruments industry median ROCE % is 2.23. LifeTech Scientific's value of 8.88% is 298.2% above this industry median. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's ROCE % compare to ABT and SYK?
LifeTech Scientific's ROCE % of 8.88% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. LifeTech Scientific's value of 8.88% is 298.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current ROCE % of 8.88% is 298.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current ROCE % is 8.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (FRA:81X) has a current ROCE % of 8.88%. The stock's GF Value™ is €0.21, compared to a current price of €0.14 — trading 33.3% below its estimated fair value. The current ROCE % is 8.88% and 298.2% above the Medical Devices & Instruments industry median of 2.23. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For LifeTech Scientific (FRA:81X), the current ROCE % is 8.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LifeTech Scientific (FRA:81X) Overvalued in 2026?

Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued. The current stock price of €0.14 is trading 33.3% below its estimated GF Value™ of €0.21.

Key valuation signals for FRA:81X:

  • ROCE %: 8.88%
  • GF Value™: €0.21 vs. price of €0.14 (33.3% below fair value)
  • GF Score™: 96/100 with 4 warning signs
  • Industry Position: 298.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:81X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LifeTech Scientific Business Description

Other Exchanges 01302:Hong Kong
Address No. 22, Keji 12th Road South, 14th Floor, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score

Get the complete analysis for FRA:81X

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.21
GF Value